All In Biotech

Drug Trial Radar · NCT05279131

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm2 on the Face or Balding Scalp in Adult Patients With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jun 28, 2022

Primary completion

Dec 28, 2022

Study completion Dec 28, 2022

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Mar 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.

Conditions

  • Keratosis, Actinic

Interventions

  • Tirbanibulin ointment 1%Drug

    Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5Time frame: Baseline, Day 5
  2. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 8Time frame: Baseline, Day 8
  3. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 15Time frame: Baseline, Day 15
  4. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 29Time frame: Baseline, Day 29
  5. Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 57Time frame: Baseline, Day 57
  6. Number of Participants With Maximum Local Tolerability Score Post-baseline for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration)Time frame: Baseline, Maximum post-baseline (up to Day 57)
  7. Time to Maximum Local Tolerability Score for Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/UlcerationTime frame: Baseline up to Day 57
  8. Local Tolerability Signs Total Composite Score by Visit at Day 5Time frame: Baseline, Day 5
  9. Local Tolerability Signs Total Composite Score by Visit at Day 8Time frame: Baseline, Day 8
  10. Local Tolerability Signs Total Composite Score by Visit at Day 15Time frame: Baseline, Day 15
  11. Local Tolerability Signs Total Composite Score by Visit at Day 29Time frame: Baseline, Day 29
  12. Local Tolerability Signs Total Composite Score by Visit at Day 57Time frame: Baseline, Day 57
  13. Maximum Local Tolerability Signs Total Composite Score Post BaselineTime frame: Baseline, Maximum post-baseline (up to Day 57)
  14. Time to Maximum Local Tolerability Total Composite ScoreTime frame: Baseline up to Day 57
  15. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 5Time frame: Baseline, Day 5
  16. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 8Time frame: Baseline, Day 8
  17. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 15Time frame: Baseline, Day 15
  18. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 29Time frame: Baseline, Day 29
  19. Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 57Time frame: Baseline, Day 57
  20. Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)Time frame: Baseline up to Day 57
  21. Number of Participants With Clinically Significant Abnormalities in Laboratory ParametersTime frame: Baseline up to Day 57
  22. Number of Participants With Clinically Significant Abnormalities in Vital SignsTime frame: Baseline up to Day 57
  23. Number of Participants With Clinically Significant Abnormalities in Physical ExaminationTime frame: Baseline up to Day 57
  24. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)Time frame: Baseline up to Day 57

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Almirall Investigation Site 7

    Hot Springs, Arkansas

  • Almirall Investigation Site 6

    Encinitas, California

  • Almirall Investigation Site 3

    Sweetwater, Florida

  • Almirall Investigation Site 5

    Rolling Meadows, Illinois

  • Almirall Investigation Site 4

    Austin, Texas

  • Almirall Investigational Site 1

    College Station, Texas

  • Almirall Investigation Site 2

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.